Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Clinical Trial to Evaluate the Safety and Efficacy of Therapeutic Hepatitis B Adenovirus Injection (T101) Combined With Nucleoside (Acid) Analogues in Chronic Hepatitis B Patients

Trial Profile

A Phase II Clinical Trial to Evaluate the Safety and Efficacy of Therapeutic Hepatitis B Adenovirus Injection (T101) Combined With Nucleoside (Acid) Analogues in Chronic Hepatitis B Patients

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Feb 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Entecavir (Primary) ; T 101 (Primary) ; Tenofovir (Primary) ; Peginterferon alfa-2a
  • Indications Hepatitis B
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Transgene Tasly (Tianjin) BioPharmaceutical

Most Recent Events

  • 05 Feb 2021 Planned primary completion date changed from 1 Dec 2020 to 30 Jun 2021.
  • 06 Dec 2020 Status changed from recruiting to active, no longer recruiting.
  • 13 Dec 2019 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top